STACLEAR is The First Fillable Syringe FDA-Cleared For Intravitreal Use
WHY INVENT AN INTRAVITREAL SYRINGE?
Floaters In The Eye Reported
The Industry Responded
Insurance companies started requiring that retina specialists have their patients sign a liability waiver before the procedure in view of this new liability risk.
The FDA Takes Steps To Ensure Patient Safety
In 2018, the Food & Drug Administration (FDA) issued new, more stringent guidelines around compounding drugs for intraocular injections, adding regulatory risk.
TriboFilm Research Was Invited to Engineer a Better Syringe:
One that meets the Food & Drug Administration's strict particulate standards for intraocular medical devices.
After 3 Years of Research & Development,
We Achieved That Goal.
Why Stop at One Problem, When We Can Fix Them All?
Our team worked closely with ophthalmologists and compounding pharmacies to understand ALL their requirements:
StaClear is the Result of Collaborative Design Thinking and
is Currently Available in Attached Needle (SC 250) and Luer Slip (SC 250-LS):
How is StaCear Superior to Generic Syringes?
StaClear 0.25 mL
LUER LOCK Syringe
The TriboFilm Research Team is Excited to Launch StaClear.
After years of R&D and a rigorous FDA process, it is gratifying to see significant market interest for StaClear, and receive positive client feedback.
VP of Technology at TriboFilm Research & Co-Inventor
We have helped many medical device & pharma companies solve difficult lubricant challenges, but the StaClear product is my absolute favorite.
Director of Technology at TriboFilm Research & Co-Inventor, StaClear
TriboFilm strives to earn customer satisfaction by consistently supplying safe, reliable, defect-free products that meet or exceed customer and regulatory requirements. To this end, we have established and are committed to the continual improvement of our Quality Management System, which is based on the requirements of 21 CFR Part 820 and ISO 13485:2016.
Principal Scientist & Quality System Manager
One of my mentors receives an intravitreal injection once a month for wet AMD. Bringing this syringe to market is personally important to me.
Director of Communications at TriboFilm Research